10-Q: iCoreConnect Inc. Reports 51% Revenue Increase in Q3 2024, But Losses Widen

iCoreConnect Inc. saw a significant revenue increase of 51% year-over-year in the third quarter of 2024, but also experienced a substantial widening of net losses.

Summary

• iCoreConnect Inc. reported a 51% increase in revenue for the nine months ended September 30, 2024, reaching $8,599,262, compared to $5,701,372 in the same period of 2023.
• The company's gross profit margin was 77% for the nine months ended September 30, 2024, compared to 74% for the same period in 2023.
• Operating expenses increased significantly to $19,382,881 for the nine months ended September 30, 2024, compared to $10,090,765 in the same period of 2023, largely due to a one-time stock compensation expense of $4,779,580.
• The company's net loss for the nine months ended September 30, 2024, was $21,609,179, a substantial increase from the $8,088,429 loss in the same period of 2023.
• The net loss attributable to common stockholders was $23,174,710 for the nine months ended September 30, 2024, compared to $8,306,945 for the same period in 2023.
• The company's cash balance decreased to $212,346 as of September 30, 2024, from $1,219,358 at the end of 2023.
• The company has a working capital deficit of $11,670,852 as of September 30, 2024.
• The company's activities were primarily financed through private placements of equity securities and issuance of debt.
• There is substantial doubt about the company's ability to continue as a going concern for the next 12 months.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with strong revenue growth offset by significant losses, a concerning cash position, and a going concern warning. The company's reliance on future funding and the identified material weaknesses in internal controls further contribute to a negative sentiment.

Positives

• The company achieved a 51% increase in revenue for the nine months ended September 30, 2024, indicating strong growth.
• Gross profit margin improved to 77% for the nine months ended September 30, 2024, suggesting better profitability on sales.
• The company continues to see organic growth in its SaaS based products.
• The company has secured contracts with larger enterprise healthcare businesses, including State Associations, Dental Support Organizations (DSOs), Hospitals, and large insurance companies.

Negatives

• The company's net loss significantly widened to $21,609,179 for the nine months ended September 30, 2024.
• Operating expenses increased substantially to $19,382,881 for the nine months ended September 30, 2024, due to a one-time stock compensation expense.
• The company's cash balance decreased to $212,346 as of September 30, 2024, indicating a liquidity concern.
• The company has a working capital deficit of $11,670,852 as of September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company is heavily reliant on future fundraising to finance its operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a significant accumulated deficit of $138,213,468.
• The company has a working capital deficit of $11,670,852.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is facing potential delisting from The Nasdaq Capital Market due to non-compliance with listing requirements.
• The company is involved in ongoing litigation in India with a potential liability of $635,000.
• The company has significant debt obligations, including convertible notes and promissory notes.

Future Outlook

The company intends to raise additional capital through the issuance of debt and/or equity securities to fund its operations and develop an improved healthcare communications system and alliances with strategic partners to generate revenues that will sustain the company. However, there is no assurance that it will be successful in raising any additional capital.

Management Comments

• Management believes in the viability of its strategy to increase revenues and in its ability to raise additional funds.
• Management's ability to continue as a going concern is ultimately dependent upon its ability to continually increase the company's customer base and realize increased revenues from signed contracts.

Industry Context

The company operates in the cloud-based software and technology sector, focusing on healthcare communication and workflow productivity. The trend towards SaaS offerings in healthcare is a positive factor for the company, but it faces competition and challenges in scaling its business and achieving profitability.

Comparison to Industry Standards

• The company's revenue growth of 51% is strong compared to many established SaaS companies, but the significant net losses and cash burn are concerning.
• The company's gross profit margin of 77% is within the range of many SaaS companies, but the high operating expenses are a major issue.
• The company's reliance on debt and equity financing is common for early-stage SaaS companies, but the going concern warning is a significant red flag.
• Compared to companies like Veeva Systems (VEEV) or athenahealth, which are established players in healthcare SaaS, iCoreConnect is still in a very early stage with significant financial challenges.
• The company's financial metrics are not comparable to established companies like Cerner (now Oracle Health) or Allscripts, which have much larger scale and profitability.

Corporate Governance

Legal Proceedings

• The company is involved in a legal dispute in India with a potential liability of approximately $635,000.

Related Party Transactions

• The company has entered into various related party transactions, including promissory notes and convertible notes with entities controlled by its Chief Executive Officer.

Stakeholder Impact

• Shareholders face the risk of potential delisting from Nasdaq and significant dilution due to the company's need for additional capital.
• Employees may be concerned about the company's financial stability and its ability to continue as a going concern.
• Customers may be concerned about the company's long-term viability and its ability to provide ongoing services.
• Creditors face the risk of potential default on the company's debt obligations.

Next Steps

• The company intends to raise additional capital through the issuance of debt and/or equity securities.
• The company plans to develop an improved healthcare communications system.
• The company intends to develop alliances with strategic partners to generate revenues.
• The company needs to regain compliance with Nasdaq listing requirements.
• The company needs to address the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

SaaS, healthcare, software, revenue, financial results, net loss, debt, equity, going concern, internal control, acquisitions, convertible notes, promissory notes, Nasdaq, litigation